Fox Run Management L.L.C. Purchases 30,162 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Fox Run Management L.L.C. grew its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 93.1% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 62,570 shares of the biopharmaceutical company’s stock after acquiring an additional 30,162 shares during the period. Fox Run Management L.L.C.’s holdings in Amicus Therapeutics were worth $589,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in Amicus Therapeutics in the third quarter valued at about $55,000. R Squared Ltd bought a new position in shares of Amicus Therapeutics during the 4th quarter valued at about $79,000. KBC Group NV lifted its holdings in shares of Amicus Therapeutics by 44.4% during the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 3,120 shares in the last quarter. Sciencast Management LP acquired a new position in shares of Amicus Therapeutics in the 4th quarter valued at approximately $100,000. Finally, Stephens Inc. AR bought a new stake in Amicus Therapeutics during the 4th quarter worth approximately $101,000.

Analyst Ratings Changes

Several research analysts have recently weighed in on FOLD shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Wells Fargo & Company reduced their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, February 20th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Amicus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.75.

Amicus Therapeutics Stock Down 3.6 %

FOLD stock opened at $8.69 on Tuesday. The company has a market cap of $2.67 billion, a price-to-earnings ratio of -48.28, a P/E/G ratio of 1.51 and a beta of 0.69. Amicus Therapeutics, Inc. has a twelve month low of $8.55 and a twelve month high of $12.65. The business has a 50 day moving average price of $9.34 and a two-hundred day moving average price of $10.04. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.